Use of pharmacogenomics in pediatric renal transplant recipients

摘要: Transplant recipients receive potent immunosuppressive drugs in order to prevent graft rejection. Therapeutic drug monitoring is the current approach guide dosing of calcineurin inhibitors, mammalian target rapamycin inhibitors (mTORi) and mofetil mycophenolate. Target concentrations used pediatric patients are extrapolated from adult studies. Gene polymorphisms metabolizing enzymes transporters such as cytochromes CYP3A4 CYP3A5, UDP-glucuronosyl transferase, P-glycoprotein known influence pharmacokinetics dose requirements immunosuppressants. The implications pharmacogenomics this patient population discussed. Genetic information can help with achieving early post-transplant period, avoiding adverse reactions drug-drug interactions. Evidence about genetic studies transplant outcomes revised.